• Cannabis Bioscience International Holdings (OTCID: CBIH) published a press release on July 20, 2026, unveiling an intranasal nanoemulsion platform for Alzheimer’s research.
• Platform targets delivery of selected cannabinoid-based or natural neuroactive compounds, positioning a multi-pathway approach rather than a single-target strategy.
• Release cites 7.4 million Americans age 65+ living with Alzheimer’s dementia in 2026, rising to 13.8 million by 2060 without breakthroughs.
• Alzheimer’s-related health and long-term care spending estimated at $409 billion in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607200700NEWSFILECNPR____20260720_305652_1) on July 20, 2026, and is solely responsible for the information contained therein.